The only therapy currently approved by the Food and Drug Administration to treat myelofibrosis, a disorder where abnormal blood cells build up inside a patient’s bone marrow, is Incyte (NASDAQ:INCY) and Novartis’ Jakafi (known as Jakavi outside the U.S.), which is a JAK2 inhibitor. JAK2 is an enzyme that plays a key role in signal transduction; therefore, blocking JAK2 can inhibit the development cytokines that lead to cancer cell proliferation. Incyte Corporation (NASDAQ:INCY) stock performance was -6.24% in last session and finished the day at $55.70. Traded volume was 3.43million shares in the last session and the average volume of the stock remained 1.83million shares. The beta of the stock remained 1.32. Incyte Corporation (NASDAQ:INCY) insider ownership is 1.00%.

Halozyme Therapeutics Inc. (NASDAQ:HALO) priced a 7,692,307 share secondary stock offering at $13.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Wednesday, the stock is now 6.4% higher than the offering price. Halozyme Therapeutics, Inc. (NASDAQ:HALO) dropped -7.98 percent to $12.46 Monday on volume of 2.96million shares. The intra-day range of the stock was $12.37 to $13.95. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has a market capitalization of $1.52billion.

Greene points to gene therapy as one of the major strategies being pursued to achieve a functional cure. Richmond, CA-based Sangamo Biosciences, Inc. (NASDAQ:SGMO) recently showed progress in its drive to modify the genes of HIV- positive patients and replicate the immunity that the “Berlin patient” acquired from his bone marrow donor. Greene says he values Sangamo Biosciences, Inc. (NASDAQ:SGMO)’s work, but he expects that most of the world’s HIV-positive population won’t be able to pay for Sangamo Biosciences, Inc. (NASDAQ:SGMO)’s multi-step procedure to modify the genes in blood cells of individual patients. Sangamo Biosciences, Inc. (NASDAQ:SGMO)’s stock on Mar 24, 2014 reported a decrease of -7.26% to the closing price of $19.80. Its fifty two weeks range is $6.86 -$24.69. The total market capitalization recorded $1.25billion. The overall volume in the last trading session was 2.91million shares. In its share capital, SGMO has 61.86million outstanding shares.

Nektar Therapeutics (NASDAQ:NKTR) has earned an average rating of “Buy” from the eight analysts that are presently covering the stock, Analyst Ratings.Net reports. On Monday, shares of Nektar Therapeutics (NASDAQ:NKTR) dropped -5.13% to close the day at $12.75. Company return on investment (ROI) is -108.20% and its monthly performance is recorded as
-6.59%. Nektar Therapeutics (NASDAQ:NKTR) quarterly revenue growth is 18.49%.